- Home
- TTWO vs BIIB Comparison
TTWO vs BIIB Comparison
Compare TTWO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTWO
- BIIB
- Stock Information
- Founded
- TTWO 1993
- BIIB 1978
- Country
- TTWO United States
- BIIB United States
- Employees
- TTWO N/A
- BIIB N/A
- Industry
- TTWO Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TTWO Technology
- BIIB Health Care
- Exchange
- TTWO Nasdaq
- BIIB Nasdaq
- Market Cap
- TTWO 40.2B
- BIIB 18.8B
- IPO Year
- TTWO 1997
- BIIB 1991
- Fundamental
- Price
- TTWO $242.56
- BIIB $125.00
- Analyst Decision
- TTWO Strong Buy
- BIIB Buy
- Analyst Count
- TTWO 23
- BIIB 27
- Target Price
- TTWO $225.00
- BIIB $188.17
- AVG Volume (30 Days)
- TTWO 2.0M
- BIIB 1.3M
- Earning Date
- TTWO 08-07-2025
- BIIB 07-31-2025
- Dividend Yield
- TTWO N/A
- BIIB N/A
- EPS Growth
- TTWO N/A
- BIIB 26.39
- EPS
- TTWO N/A
- BIIB 10.12
- Revenue
- TTWO $5,633,600,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- TTWO $8.35
- BIIB N/A
- Revenue Next Year
- TTWO $53.69
- BIIB N/A
- P/E Ratio
- TTWO N/A
- BIIB $12.41
- Revenue Growth
- TTWO 5.31
- BIIB 1.59
- 52 Week Low
- TTWO $135.24
- BIIB $110.04
- 52 Week High
- TTWO $245.08
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- TTWO 59.19
- BIIB 45.14
- Support Level
- TTWO $235.55
- BIIB $123.21
- Resistance Level
- TTWO $245.08
- BIIB $129.27
- Average True Range (ATR)
- TTWO 4.81
- BIIB 3.00
- MACD
- TTWO 0.37
- BIIB -0.77
- Stochastic Oscillator
- TTWO 62.88
- BIIB 21.06
About TTWO Take-Two Interactive Software Inc.
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.